表達載體市場 - 全球產業規模、佔有率、趨勢、機會、預測：按宿主類型、應用、最終用戶、地區和競爭對手分類，2021-2031年

全球表達載體市場預計將從 2025 年的 4.5158 億美元成長到 2031 年的 6.1141 億美元，複合年成長率為 5.18%。

表達載體，即基因改造的質體或病毒，在將特定基因序列導入目標細胞以進行蛋白質生產或治療性修飾方面發揮著至關重要的作用。該市場的成長主要受細胞和基因治療技術進步、遺傳疾病發病率上升以及生物製藥需求不斷成長的驅動。這些因素是持續成長要素，預示著個人化基因治療和重組蛋白生產將長期發展，而這需要高效的基因遞送系統。

推動市場擴張的還有產業的積極努力，這些努力直接影響載體的需求。例如，再生醫學聯盟報告稱，到2024年，細胞和基因治療領域的投資將增加30%，臨床試驗數量將增加3%。如此大量的資金流入凸顯了對錶達技術的持續需求，以支持這些不斷發展的治療方法。然而，可擴展載體生產（尤其是病毒載體）的高成本和複雜性是可能阻礙這些技術廣泛應用的重大障礙。

市場促進因素

基因治療和基因組編輯技術的顯著進步正在從根本上改變全球表達載體市場，從而催生了對先進遞送系統的迫切需求。隨著臨床研發管線從針對罕見單基因疾病擴展到涵蓋更廣泛的適應症，臨床試驗和商業應用中對病毒載體和非病毒載體的需求都在急劇成長。儘管面臨普遍的經濟挑戰，臨床研發的持續活躍也清楚地印證了這一趨勢。正如美國基因與細胞治療學會 (ASGCT) 在 2025 年第三季基因、細胞和 RNA 治療趨勢報告（2025 年 11 月）中所述，全球研發管線依然強勁，目前全球有超過 3200 項臨床試驗正在進行中。穩定的高效價、GMP 級載體供應對於如此廣泛的臨床研究至關重要，這迫使製造商不斷創新載體設計，以確保這些新一代療法的安全高效遞送。

合約研究與生產組織 (CRO/CDMO) 服務的成長在應對複雜載體生產固有的挑戰方面發揮著至關重要的作用，從而擴大了市場產能。生物製藥公司擴大將載體生產外包給擁有必要產業規模和監管知識的專業合作夥伴。這種轉變反映在主要產業參與者的財務表現。例如，牛津生物醫學公司 (Oxford Biomedica) 發布的「截至 2025 年 6 月 30 日的六個月中期業績」（2025 年 9 月）顯示，總收入成長 44% 至 7320 萬英鎊，這主要得益於對慢病毒載體生產的強勁需求。此外，根據 DCAT 價值鏈洞察 (DCAT Value Chain Insights) 的數據，為了提升產能，正在進行大規模，例如富士膠片迪奧辛生物技術公司(FUJIFILM Diosin Biotechnologies) 於 2025 年在北卡羅來納州投資 32 億美元建設商業規模的生物製造工廠。此類策略擴張確保了表達載體的基本需求能夠得到適當的產業產能滿足。

市場挑戰

可擴展載體生產的高成本和複雜技術特性嚴重阻礙了全球表達載體市場的擴張。病毒載體的生產涉及難以標準化的複雜生物學過程，通常導致產量低、生產成本極高。這些生產限制導致臨床級材料的供應不足，使得許多研發者難以將候選產品推進早期臨床階段之後。此外，建造和維護符合GMP標準的設施需要大量資本投入，這進一步減少了能夠維持商業性運營的公司數量，從而設置了准入壁壘，抑制了競爭和創新。

這種結構性障礙導致市場上的成功集中在少數幾種治療方法上。根據再生醫學聯盟2025年的數據，該領域75%的全球銷售額將來自不到10種產品。這一數字凸顯了新參與企業由於生產困難而面臨的實現商業性獲利能力的巨大挑戰。無法以經濟高效的方式擴大生產規模阻礙了這些先進技術的廣泛應用，使其無法應用於更常見的疾病，並將市場限制在專業化的高價值治療方法上。

市場趨勢

將人工智慧 (AI) 整合到載體最佳化中，正顯著改變表達載體的設計階段，利用生成模型預測衣殼效率和免疫逃脫能力。這項技術進步使開發人員能夠繞過傳統試驗篩檢的限制，並顯著加速組織特異性基因遞送系統的開發。近期一些重要的策略合作，著重於利用機器學習進行治療藥物設計，體現了業界對這些計算工具的重視。例如，BioSpace 在 2024 年 9 月報道稱，人工智慧公司 Generate: Biomedicines 已與諾華公司合作，投資高達 10 億美元，利用其生成式人工智慧平台最佳化新型蛋白質模式。這項進展凸顯了市場正朝著數據驅動的載體工程方向發生根本性轉變，以縮短研發週期。

同時，合成生物學在載體工程中的日益普及正在提高基因有效載荷的準確性和可擴展性。製造商正逐步摒棄傳統的、可變的克隆技術，轉而利用高精度合成DNA合成技術來建構複雜的載體骨架。這種操作方式的轉變滿足了臨床級材料精準定序的關鍵需求，並直接支持了不斷擴展的基因治療產品線。不斷成長的行業需求也得到了以金額為準的佐證。根據Twist Bioscience發布的2024會計年度第三季財報（2024年8月），其合成生物學（SynBio）業務的銷售額達到3,300萬美元，主要得益於合成基因和片段的供應。這一成長凸顯了該行業對合成平台的依賴，以克服生產難題並確保符合監管標準。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球表達載體市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依宿主類型（細菌表達載體、哺乳動物表達載體、昆蟲表達載體、酵母表達載體、其他）
  • 按應用領域（治療、研究、其他）
  • 依最終用戶（製藥/生技、學術研究、其他）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美表達式向量市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲表達載體市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區表達向量市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲表達載體市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美表達載體市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球表達載體市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Thermo Fisher Scientific, Inc.,
• Promega Corporation
• Agilent Technologies, Inc.
• Bio-Rad Laboratories Inc.
• QIAGEN NV
• Merck KGaA
• TAKARA HOLDINGS Inc.
• GenScript Corp.
• Quest Diagnostics
• Addgene, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Expression Vector Market is projected to expand from USD 451.58 Million in 2025 to USD 611.41 Million by 2031, exhibiting a Compound Annual Growth Rate (CAGR) of 5.18%. Expression vectors, which are engineered plasmids or viruses, play a crucial role in introducing specific gene sequences into target cells for the production of proteins or for therapeutic modifications. The market's growth is fundamentally propelled by the increasing development of cell and gene therapies, the growing incidence of genetic disorders, and the rising need for biologic drugs. These elements represent enduring drivers, signifying a lasting shift towards personalized genetic medicine and recombinant protein production, both of which require effective gene delivery systems.

Further illustrating this market's expansion is substantial industry engagement directly impacting vector demand. For instance, the Alliance for Regenerative Medicine reported a 30 percent increase in investment and a 3 percent rise in clinical trials within the cell and gene therapy sector in 2024. This significant capital inflow highlights the ongoing necessity for expression technologies to support these advancing therapies. Nevertheless, the considerable expense and intricate nature of scalable vector manufacturing, particularly concerning viral vectors, present a notable obstacle that may hinder the broader adoption rate of these technologies.

Market Driver

Significant progress in gene therapy and genome editing technologies is profoundly transforming the Global Expression Vector Market, generating a pressing demand for advanced delivery systems. As clinical pipelines evolve from addressing rare monogenic disorders to encompassing wider indications, the need for viral and non-viral vectors for both clinical trials and commercial applications has dramatically increased. This trend is clearly demonstrated by persistent high activity in clinical development, even amid broader economic challenges. As reported by the American Society of Gene & Cell Therapy in its 'Q3 2025 Gene, Cell, + RNA Therapy Landscape Report' (November 2025), the global pipeline remains strong with over 3,200 trials underway worldwide. This extensive clinical work necessitates a steady supply of high-titer, GMP-grade vectors, thereby driving manufacturers to innovate in vector design to ensure the safety and efficient transduction of these next-generation therapeutics.

The growth of Contract Research and Manufacturing Organization (CRO/CDMO) services plays a crucial role in amplifying market capabilities by addressing the manufacturing challenges inherent in complex vector production. Biopharmaceutical companies are increasingly delegating vector production to expert partners equipped with the necessary industrial scale and regulatory knowledge. This transition is reflected in the financial outcomes of major industry players; for example, Oxford Biomedica's 'Interim Results for the Six Months Ended 30 June 2025' (September 2025) indicated a 44% surge in total revenues to £73.2 million, largely fueled by robust demand for lentiviral vector manufacturing. Additionally, substantial infrastructure investments are being made to bolster this capacity, as exemplified by Fujifilm Diosynth Biotechnologies' 2025 opening of a $3.2 billion commercial-scale biomanufacturing facility in North Carolina, as per DCAT Value Chain Insights. Such strategic expansions ensure that the foundational demand for expression vectors is met with appropriate industrial capability.

Market Challenge

The considerable expense and intricate technical nature of scalable vector manufacturing significantly impede the expansion of the Global Expression Vector Market. The production of viral vectors involves complex biological procedures that are challenging to standardize, frequently leading to low yields and exceptionally high production costs. These manufacturing limitations constrain the availability of clinical-grade materials, rendering it financially impractical for many developers to advance their product candidates beyond initial clinical stages. The substantial capital investment required to build and sustain GMP-compliant facilities further reduces the number of companies able to maintain commercial operations, thereby establishing a barrier to entry that hinders both competition and innovation.

This inherent structural barrier has resulted in a market where success is highly concentrated among a limited number of therapies. Data from the Alliance for Regenerative Medicine in 2025 revealed that 75 percent of the global revenue in the sector originated from fewer than 10 products. This figure highlights the significant challenges faced by new market entrants in achieving commercial viability due to manufacturing difficulties. The inability to scale production cost-effectively prevents the widespread adoption of these advanced technologies, restricting the market to specialized, high-value treatments rather than allowing for expansion into more common disease applications.

Market Trends

The integration of Artificial Intelligence (AI) for vector optimization is profoundly transforming the design stage of expression vectors, employing generative models to forecast capsid efficiency and immune evasion. This technological advancement enables developers to circumvent the constraints of traditional trial-and-error screening, thereby considerably speeding up the development of tissue-specific gene delivery systems. Industry dedication to these computational tools is apparent in recent significant strategic partnerships focused on utilizing machine learning for therapeutic design. For example, BioSpace reported in September 2024 that Generate:Biomedicines, an AI company, entered into a partnership worth up to $1 billion with Novartis to apply its generative AI platform for optimizing novel protein modalities. This trend highlights the market's fundamental shift towards data-driven vector engineering to shorten development timelines.

Concurrently, the increasing adoption of synthetic biology in vector engineering is improving the precision and scalability of genetic payloads. Manufacturers are progressively using high-fidelity synthetic DNA synthesis to build intricate vector backbones, moving away from conventional cloning techniques that are susceptible to variability. This operational change addresses the crucial requirement for accurate sequences in clinical-grade materials, directly supporting the growing pipeline of gene therapies. This escalating industrial demand is measurable; Twist Bioscience's 'Fiscal Third Quarter 2024 Financial Results' (August 2024) indicated that SynBio revenue climbed to $33.0 million, specifically driven by the provision of synthetic genes and fragments. Such growth emphasizes the sector's dependence on synthetic platforms to overcome manufacturing challenges and ensure adherence to regulatory standards.

Key Market Players

• Thermo Fisher Scientific, Inc.,
• Promega Corporation
• Agilent Technologies, Inc.
• Bio-Rad Laboratories Inc.
• QIAGEN NV
• Merck KGaA
• TAKARA HOLDINGS Inc.
• GenScript Corp.
• Quest Diagnostics
• Addgene, Inc.

Report Scope

In this report, the Global Expression Vector Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Expression Vector Market, By Host Type

• Bacterial expression vectors
• Mammalian expression vectors
• Insect expression vectors
• Yeast expression vector
• Others

Expression Vector Market, By Application

• Therapeutic
• Research
• Others

Expression Vector Market, By End User

• Pharmaceutical & biotech
• Academic research
• Others

Expression Vector Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Expression Vector Market.

Available Customizations:

Global Expression Vector Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Expression Vector Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Host Type (Bacterial expression vectors, Mammalian expression vectors, Insect expression vectors, Yeast expression vector, Others)
  • 5.2.2. By Application (Therapeutic, Research, Others)
  • 5.2.3. By End User (Pharmaceutical & biotech, Academic research, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Expression Vector Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Host Type
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Expression Vector Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Host Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Expression Vector Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Host Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Expression Vector Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Host Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Expression Vector Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Host Type
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Expression Vector Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Host Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France Expression Vector Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Host Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Expression Vector Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Host Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Expression Vector Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Host Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Expression Vector Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Host Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific Expression Vector Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Host Type
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Expression Vector Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Host Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Expression Vector Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Host Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Expression Vector Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Host Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Expression Vector Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Host Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Expression Vector Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Host Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa Expression Vector Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Host Type
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Expression Vector Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Host Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Expression Vector Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Host Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Expression Vector Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Host Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America Expression Vector Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Host Type
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Expression Vector Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Host Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Expression Vector Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Host Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Expression Vector Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Host Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Expression Vector Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific, Inc.,
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Promega Corporation
• 15.3. Agilent Technologies, Inc.
• 15.4. Bio-Rad Laboratories Inc.
• 15.5. QIAGEN NV
• 15.6. Merck KGaA
• 15.7. TAKARA HOLDINGS Inc.
• 15.8. GenScript Corp.
• 15.9. Quest Diagnostics
• 15.10. Addgene, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer